C5a receptor antagonists for the treatment of inflammation.
The anaphylatoxin C5a is a classic, potent inflammatory mediator, with biological activities that have been implicated in a variety of diseases. As a result of two decades of study, C5a receptor antagonists that prevent high-affinity binding of C5a to its receptor have been discovered, which show therapeutic effects in various inflammatory disease models. Moreover, the involvement of C5a in disease models has been demonstrated in various experiments using C5/C5a receptor-deficient mice and anti-C5/C5a antibodies. It is therefore anticipated that these antagonists will have potential as novel anti-inflammatory therapeutics.
Sumichika
Hiroshi
H
Research Laboratory III (Immunology), Pharmaceuticals Research Division, Mitsubishi Pharma Co, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan. sumichika.hiroshi@mg.m-pharma.co.jp
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015936:Complement C5a / Q000378:metabolism; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D044087:Receptor, Anaphylatoxin C5a / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
D000893:Anti-Inflammatory Agents; D044087:Receptor, Anaphylatoxin C5a; D015936:Complement C5a